Focus: Neuraly is a clinical-stage biotech focused on PEGylated small molecules targeting metabolic diseases and neurology. The company is headquartered in Gaithersburg, MD and operates with a pre-revenue, pipeline-driven model.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Neuraly to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Neuraly
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Neuraly's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight - Business Upturn
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight Business Upturn
D&D Pharmatech, chosen for SOLAR ‘Shark Tank,’ presents Phase 2 data on zabopegdutide - 더바이오
D&D Pharmatech, chosen for SOLAR ‘Shark Tank,’ presents Phase 2 data on zabopegdutide 더바이오
D&D Pharmatech to Present Phase 2 Results of Zabopegdutide at SOLAR Conference 2026 - Aju Press
D&D Pharmatech to Present Phase 2 Results of Zabopegdutide at SOLAR Conference 2026 Aju Press
D&D Pharmatech to Present Zabopegdutide Phase 2 Trial Results at SOLAR Shark Tank - 아시아경제
D&D Pharmatech to Present Zabopegdutide Phase 2 Trial Results at SOLAR Shark Tank 아시아경제
D&D Pharmatech to Present Zavopegdutide Phase 2 Results at SOLAR Conference - Seoul Economic Daily
D&D Pharmatech to Present Zavopegdutide Phase 2 Results at SOLAR Conference Seoul Economic Daily
D&D Pharmatech to Present Zavopegdutide Phase 2 Results at SOLAR Conference - Seoul Economic Daily
D&D Pharmatech to Present Zavopegdutide Phase 2 Results at SOLAR Conference Seoul Economic Daily
Showing 6 of 9 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics.
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Showing 5 of 8 publications